Evaluating the Effects of CDK Inhibitors in Ischemia–Reperfusion Injury Models
Publisher
Springer New York
Reference17 articles.
1. Orzaez M, Guevara T, Sancho M, Perez-Paya E (2012) Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. Cell Death Dis 3:e415
2. Iyirhiaro GO, Brust TB, Rashidian J, Galehdar Z, Osman A, Phillips M, Slack RS, Macvicar BA, Park DS (2008) Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia. J Neurochem 105(3):703–713
3. Hilton GD, Stoica BA, Byrnes KR, Faden AI (2008) Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J Cereb Blood Flow Metab 28(11):1845–1859
4. Menn B, Bach S, Blevins TL, Campbell M, Meijer L, Timsit S (2010) Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 5(8):e12117
5. Guevara T, Sancho M, Perez-Paya E, Orzaez M (2014) Role of CDK5/cyclin complexes in ischemia-induced death and survival of renal tubular cells. Cell Cycle 13(10):1617–1626